The Dementia Discovery Fund (DDF) and Immuneering have formed a partnership to identify new therapy targets and candidates for Alzheimer’s disease. DDF will invest $1.3 million to use Immuneering’s proprietary computational drug discovery platform and analyze available public data of Alzheimer’s disease patients. Immuneering researchers use those…
COR388, Cortexyme‘s investigational compound to treat Alzheimer’s, was safe and well-tolerated in healthy volunteers taking part in a Phase 1 clinical trial, the company announced. COR388 is a first-in-class bacterial protease inhibitor designed to target a specific bacteria that has been identified in both the brain tissue and cerebrospinal…
Sokhey announced it recently launched Swann VR, the world’s first virtual reality memory training device specifically designed for people with Alzheimer’s disease. The company, and product, were created by Taegh Sokhey, a Northwestern University student planning to start medical school. “Patients now have an effective tool that they can…
The Boston Red Sox hosted Cure Alzheimer’s Fund at a recent baseball game against the Detroit Tigers to raise awareness about Alzheimer’s and bring attention to the nonprofit group’s support for research into new treatments and ways of preventing or curing this disease. The event included a ceremony…
June is World Alzheimer’s and Brain Awareness Month, and James E. Galvin, MD, MPH, a leading neuroscientist and associate dean at Florida Atlantic University’s Charles E. Schmidt College of Medicine, has compiled a list of myths and truths about the disease. According to Galvin, some…
Cognition Therapeutics has received two multi-year grants from the National Institute on Aging (NIA) totaling $6.6 million to fund two clinical studies of Elayta (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease. Elayta is a brain-penetrating small molecule with a unique disease-modifying mechanism of…
UsAgainstAlzheimer’s recently launched the Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE) initiative as a groundbreaking partnership between the public and private sectors to identify and prioritize the needs and preferences of those living with Alzheimer’s disease. The organization recently held a webinar to present the AD…
A new Facebook app can provide emotional support to unpaid caregivers of Alzheimer’s disease patients, according to a study. Researchers at Indiana University Purdue University Indianapolis developed the app as part of an investigation that looked at “friendsourcing” as a type of peer support group intervention. In particular, they wanted to…
A new National Institute on Aging (NIA)-funded collaborative project will bring together scientists from different disciplines to study a range of issues affecting older adults, including Alzheimer’s disease. The Research Centers Collaborative Network (RCCN) will be funded with $2.5 million over year years by the NIA at the National…
Biogen and Ionis Pharmaceuticals are expanding their strategic collaboration through a new 10-year agreement to develop novel RNA-targeted therapy candidates for a broad range of neurological diseases, including Alzheimer’s disease. This agreement builds on the collaboration that produced Spinraza (nusinersen), the first and only approved treatment…
Get regular updates to your inbox.